Posted by Michael Wonder on 20 Jun 2024
Truqap plus Faslodex approved in the EU for patients with advanced oestrogen receptor positive breast cancer
20 June 2024 - Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% versus Faslodex alone in a biomarker-altered population.
AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in the European Union for the treatment of adult patients with oestrogen receptor positive, HER2 negative locally advanced or metastatic breast cancer with one or more PIK3CA, AKT1, or PTEN alterations following recurrence or progression on or after an endocrine-based regimen.
